Reconsidering the Role of Nebulization in the Maintenance Treatment of COPD

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reconsidering the Role of Nebulization in the Maintenance Treatment of COPD

Program Information

Program Information

ReachMD Healthcare Image

Amid the substantial and growing burden of chronic obstructive pulmonary disease, is it time to rethink the role of nebulization?

  • Sponsored by

  • Overview

    With an estimated 65 million people around the world currently suffering from moderate to severe chronic obstructive pulmonary disease (COPD), its burden is undoubtedly substantial and growing. That’s why it’s so important to stay up to date on the various treatment options available, and joining Dr. Jennifer Caudle to talk about YUPELRI, the first and only once-daily nebulized LAMA indicated for the maintenance treatment of patients with COPD, is Dr. Donald Mahler.

    Case based on real patient. Patient's name has been changed. Image is actor portrayal.

    Dr. Caudle and Dr. Mahler have been compensated for their participation.

    VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company. THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

    © 2022 Viatris Inc. All Rights Reserved. REV-2021-0340


    YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).


    YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

    YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, such as a rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

    As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately, and alternative therapy should be instituted.

    YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos, or colored images in association with red eyes from conjunctival congestion and corneal edema.

    Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

    Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

    The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

    Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

    YUPELRI is not recommended in patients with any degree of hepatic impairment.

    Please see accompanying Full Prescribing Information.

    For additional information please contact us at 1-800-395-3376.

Schedule5 Dec 2022